ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1438

Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention

Toktam Kainifard1, Manjit Saluja2, Anuradha Venugopalan3, Raju Rane4 and Arvind Chopra5, 1Rheumatology, PhD fellow, Pune, India, 2Clinical care, Center for Rheumatic Diseases, Pune, India, 3Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, 4Pathology, Pathologist, Pune, India, 5Rheumatology, Centre for Rheumatic Diseases, Pune 411001, India

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: dietary supplements, non-pharmacologic intervention, pain management and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Pain: Basic and Clinical Aspects Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

National Health and Nutrition Survey III (1988-94,USA) data showed a low K+ body status in RA. Further information is scanty. K+ is critical to ‘pain’ [nociceptive processing, K+ ion channel downregulation (Tsantoulas. Trends Neurosci 2014; 37:146) and related process e.g. oxidant tissue damage and T lymphocytes function [K2P5.1 (Bitner. Arthritis Res Therapy 2011;13:R 21), Kv1.3 & KCa3.1 channels (Lam. Drug Dev Res 2011; 72: 573] and cortisol secretion. Using Indian standards (National Institute of Nutrition, Hyderabad) and controlled diet survey, we showed that K+ was low (p<0.5) in RA patients, more so in women (EULAR 2014).

Methods: 172 consenting chronic RA patients (ACR 1987 classified, mean age 49.9 years, 89 % women, mean duration 9.9 years,74% seropositive RF) with active pain(visual analogue scale > 4 cm) were randomized into an assessor blind, three arm study of 16 week duration in a community rheumatology center. Standardized oral K+ intake was based on K+ rich vegetarian balanced diet in Arm A (3.5-4 gm K+ daily) and an additional K+ supplement powder (K+ rich pulses & seeds plus oral rehydration salt(3 gm K+), Indian pharmacopeia) in Arm B (7.5-8 gm K+ daily); local diet preferences considered. Arm C was control (routine diet , 2-3 gm K+ daily). Patients continued pre-study suprvised standard rheumatology care/drugs (72% methotrexate, mean weekly dose 14 mg;60% prednisolone, mean4 mg daily); analgesic rescue permitted and monitored as per protocol. No other non-drug intervention advised. Standard efficacy/safety measures and diet intake were evaluated every month. Compliance check included urinary K+ assay. The study (80% power, significant p <0.05) was analyzed using SPSS; NS: p, not significant. Arms were well matched for several measures (for mean DAS 28: A=4.9; B=5.5; C=4.9) and withdrawals (A: 8.8%; B:12.1%; C: 8.8%).  

Results:

Pain and several ACR efficacy measures improved (P<0.05) by intervention; difference was NS by intent to treat analysis/ITT (mean change pain VAS: A=-1.3 cm; B=2 cm; C= 1.2; p=0.17, ANOVA).But completer analysis showed significant change (p=0.04) in mean pain VAS in the B intervention arm (high K+ intake). B arm also showed best response (ITT, P<0.05) in proportion patients with at least 50% reduction and minimal clinical important difference in pain VAS on completion from baseline. Maximum improvement (NS) in HAQ (Indian validated version) and SF 36 physical score was seen in the B arm. There was reduction (NS) in the mean DAS 28 score by intervention (A:-1.4; B:-1.2; C: -0.9). Only mild AE were reported (<8% patients by study arm). On completion, B arm demonstrated a maximum serum cortisol (AM) increase. K+ intervention arms showed reduction in systolic BP. Ongoing medication, dietary factors and compliance, disease activity status may confound results.

Conclusion:

This pragmatic interventional control study in patients suffering from  chronic symptomatic RA  showed a clinically important pain reduction over and above standard drug treatment using dietary K+ augmentation. Other possible benefits were reduced disease activity and improved BP (cardiovascular) status. Overall, this seemed to be a gentle useful and safe adjunct therapy.


Disclosure: T. Kainifard, None; M. Saluja, None; A. Venugopalan, None; R. Rane, None; A. Chopra, None.

To cite this abstract in AMA style:

Kainifard T, Saluja M, Venugopalan A, Rane R, Chopra A. Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/oral-potassium-k-reduces-pain-in-ra-a-randomized-active-control-study-of-diet-based-k-intervention/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oral-potassium-k-reduces-pain-in-ra-a-randomized-active-control-study-of-diet-based-k-intervention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology